This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer

This study has been terminated.
(From preliminary imaging data, the study was stopped due to futility.)
Information provided by (Responsible Party):
University of Virginia Identifier:
First received: June 19, 2013
Last updated: March 16, 2016
Last verified: March 2016
The purpose of this clinical trial is to study an experimental drug called PTP-01 that is being used as an imaging agent to diagnosis pancreatic cancer. Currently, pancreatic cancer is diagnosed using CT or MRI scans which miss small pancreatic cancers, particularly early stage disease. Researchers at the University of Virginia have identified a biomarker for pancreatic cancer called plectin, which is very specific for pancreatic cancer and not other, non-cancerous conditions involving the pancreas. These researchers have also developed PTP-01, an experimental drug that may be used with SPECT imaging to detect pancreatic cancer cells in humans.

Condition Intervention Phase
Pancreatic Ductal Adenocarcinoma Drug: PTP-01 Early Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Phase 0, Open Label Study to Evaluate the Biodistribution and Pharmacokinetics of a Single Intravenous Bolus Dose of PTP-01 in Subjects With Resectable Pancreatic Ductal Adenocarcinoma

Further study details as provided by University of Virginia:

Primary Outcome Measures:
  • Ability of PTP-01 to detect pancreatic ductal adenocarcinoma [ Time Frame: up to 72 hours post dose ]
    requires a signal to background ratio of greater than or equal to 2:1 following a single intravenous bolus of PTP-01

Secondary Outcome Measures:
  • Biodistribution and Binding Characteristics of PTP-01 [ Time Frame: up to 7 days post dose ]
    Assessments will be made from imaging (whole body planar and SPECT/CT) and blood draws following PTP-01 dose. Tissue samples will also be retained for pathology.

  • Clearance of PTP-01 [ Time Frame: up to 7 days post dose ]
    Blood and urine samples will be collected to measure the level of radioactivity at specified intervals following PTP-01 dose.

  • Safety and Tolerability of PTP-01 [ Time Frame: up to 30 days post dose ]
    Clincial labs, ECGs, vital signs and physical exams will be performed up to 7 days post dose. Adverse events will be collected up to 30 days post dose.

Enrollment: 3
Study Start Date: November 2013
Study Completion Date: January 2016
Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PTP-01
single IV bolus dose 24 hours prior to surgery
Drug: PTP-01
Dose level 1 is 10mCi (50ug of peptide)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • subject is undergoing resection of pancreas for pancreatic ductal adenocarcinoma (PDAC)
  • subject must have adequate renal function
  • ECOG performance status of 0-2
  • women of child-bearing age and men must agree to use contraception prior to and during the study

Exclusion Criteria:

  • subjects receiving any other investigational agents
  • significant history of uncontrolled cardiac disease or central nervous system (CNS) disease
  • pregnant or breastfeeding women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01962909

United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
University of Virginia
Principal Investigator: Reid Adams, MD University of Virginia
  More Information

Responsible Party: University of Virginia Identifier: NCT01962909     History of Changes
Other Study ID Numbers: 16678
Study First Received: June 19, 2013
Last Updated: March 16, 2016

Keywords provided by University of Virginia:
Pancreatic Resection

Additional relevant MeSH terms:
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms processed this record on August 17, 2017